Inhaled budesonide and beclomethasone for the prevention and treatment of bronchopulmonary dysplasia in very preterm infants: a prospective randomized controlled trial - Scorecard - MDSpire
Advertisement
Inhaled budesonide and beclomethasone for the prevention and treatment of bronchopulmonary dysplasia in very preterm infants: a prospective randomized controlled trial
Clinical Scorecard: Efficacy of Inhaled Budesonide and Beclomethasone in Preventing and Treating Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Prospective Randomized Controlled Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Very preterm infants at high risk of BPD, aged >7 days requiring non-invasive respiratory support, specifically those born <28 weeks gestation.
Care Setting
Key Highlights
Clarify that the lack of significant differences in BPD incidence and severity suggests inhaled corticosteroids may not be effective in reducing these outcomes.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Assess respiratory support duration, incidence of adverse outcomes, and specific parameters such as blood pressure and infection rates.
Risks
Patient & Prescribing Data
Inhaled budesonide (0.5 mg) and beclomethasone (0.4 mg) administered every 12 hours showed efficacy in reducing respiratory support duration; contraindications should be noted.
Clinical Best Practices
Initiate inhaled corticosteroids after the first week of life, ideally considering gestational age.
In a multicenter registry study, genetic diagnoses were associated with substantially lower cognitive, language, and motor scores; while birth weight, surgical timing, hospitalization burden, and caregiver education were also associated with outcomes.
